The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model

Brain Res. 2005 Mar 15;1038(1):1-10. doi: 10.1016/j.brainres.2004.12.055.

Abstract

Vascular endothelial growth factor (VEGF) has previously been shown to display neuroprotective effects on dopaminergic (DA) neurons. In this study, we investigated whether the effects of VEGF were dose-dependent or not. First, VEGF was shown to be neuroprotective on 6-hydroxydopamine (6-OHDA)-treated murine DA neurons in vitro, although the 1 ng/ml of VEGF displayed more neuroprotective effects than 100 ng/ml. Furthermore, using 2 sizes of capsules (small/large) with different secreting quantities, 6-OHDA-treated rats receiving the small capsule filled with VEGF-secreting cells (BHK-VEGF) into the striatum showed a significant decrease in amphetamine-induced rotational behavior in number and a significant preservation of TH-positive fibers compared to those receiving the large BHK-VEGF capsule as well as those receiving BHK-Control capsule. Rats receiving the large BHK-VEGF capsule showed much more glial proliferation, angiogenesis, and brain edema around the capsule than those with the small one. High-dose administration of VEGF might cause poor circulation related to brain edema, although low-dose administration of VEGF displays neuroprotective effects on DA neurons. Our results demonstrate the importance of administration dose of VEGF, suggesting that low-dose administration of VEGF might be desirable for Parkinson's disease.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphetamine / pharmacology
  • Animals
  • Cell Survival / drug effects
  • Disease Models, Animal
  • Dopamine / metabolism*
  • Dopamine Agents / pharmacology
  • Dose-Response Relationship, Drug
  • Drug Implants
  • Female
  • In Vitro Techniques
  • Mesencephalon / cytology
  • Mesencephalon / drug effects
  • Mice
  • Mice, Inbred C57BL
  • Neostriatum / drug effects
  • Nerve Degeneration / chemically induced
  • Neurons / cytology
  • Neurons / drug effects*
  • Neuroprotective Agents / administration & dosage*
  • Oxidopamine
  • Parkinson Disease / drug therapy*
  • Rats
  • Rats, Sprague-Dawley
  • Tyrosine 3-Monooxygenase / metabolism
  • Vascular Endothelial Growth Factor A / administration & dosage*

Substances

  • Dopamine Agents
  • Drug Implants
  • Neuroprotective Agents
  • Vascular Endothelial Growth Factor A
  • Oxidopamine
  • Amphetamine
  • Tyrosine 3-Monooxygenase
  • Dopamine